300194.SHE Fuan Pharmaceutical Group Co
- Market cap
- CNY 4.24B
- P/E
- 178.0x
- P/B
- 0.96x
- ROE
- 3.7%
- Dividend yield
- 2.48%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300194.SHE undervalued?
Graham number300194.SHE trades 175.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fuan Pharmaceutical Group Co fundamental analysis
No fundamental analysis for Fuan Pharmaceutical Group Co yet.
Fuan Pharmaceutical Group Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd. in Augus…
Full company profileFuan Pharmaceutical Group Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fuan Pharmaceutical Group Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.30B | 2.09B | 2.67B | 2.78B | 2.37B | 2.45B | 2.42B | 2.65B | 2.39B | 1.74B | 1.63B |
| Gross Profit | 590M | 1.16B | 1.61B | 1.75B | 1.53B | 1.52B | 1.36B | 1.37B | 1.22B | 643M | 646M |
| Operating Income | 256M | 329M | -321M | 327M | 241M | -591M | 179M | 298M | 321M | 96.4M | 183M |
| EBITDA | 389M | 482M | -180M | 474M | 408M | -396M | 401M | 529M | 533M | 311M | 196M |
| Net Income | 222M | 285M | -360M | 293M | 209M | -297M | 205M | 232M | 280M | 77.0M | 165M |
| EPS | 0.19 | 0.24 | -0.30 | 0.25 | 0.18 | -0.25 | 0.17 | 0.19 | 0.24 | 0.06 | 0.14 |
| Balance Sheet | |||||||||||
| Total Assets | 4.40B | 4.69B | 4.29B | 4.74B | 5.97B | 5.71B | 5.88B | 5.98B | 5.98B | 5.76B | 5.56B |
| Total Liabilities | 434M | 518M | 599M | 747M | 1.42B | 1.84B | 1.93B | 1.83B | 1.58B | 1.40B | 1.13B |
| Shareholders' Equity | 3.96B | 4.17B | 3.69B | 3.99B | 4.10B | 3.73B | 3.95B | 4.14B | 4.40B | 4.36B | 4.43B |
| Cash & Short-term Investments | 277M | 353M | 601M | 862M | 929M | 1.00B | 704M | 997M | 876M | 887M | 647M |
| Total Debt | 54.0M | - | 87.0M | 116M | 602M | 906M | 714M | 838M | 527M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 374M | 453M | 268M | 296M | 163M | 257M | 339M | 329M | 304M | 312M | - |
| Capital Expenditure | 154M | 84.6M | 132M | 224M | 345M | 413M | 383M | 216M | 242M | 108M | 118M |
| Free Cash Flow | 220M | 369M | 136M | 71.8M | -182M | -156M | -43.6M | 113M | 61.8M | 204M | 181M |
| Ratios | |||||||||||
| ROE | 5.6% | 6.8% | -9.7% | 7.3% | 5.1% | -8.0% | 5.2% | 5.6% | 6.4% | 1.8% | 3.7% |
| ROA | 5.0% | 6.1% | -8.4% | 6.2% | 3.5% | -5.2% | 3.5% | 3.9% | 4.7% | 1.3% | 3.0% |
| Net Profit Margin | 17.1% | 13.6% | -13.5% | 10.5% | 8.8% | -12.1% | 8.4% | 8.8% | 11.7% | 4.4% | 10.1% |
| Debt to Equity | 0.01x | - | 0.02x | 0.03x | 0.15x | 0.24x | 0.18x | 0.20x | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fuan Pharmaceutical Group Co dividends
- Dividend yield
- 2.48%
- Forward dividend
- 0.07 CNY
- Payout ratio
- 136.4%
- Ex-dividend date
- May 28, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 105M | 0.09 | 136.4% |
| 2024 | CNY 84.2M | 0.07 | 30.1% |
| 2023 | CNY 94.0M | 0.08 | 40.5% |
| 2022 | CNY 28.1M | 0.02 | 13.7% |
| 2021 | CNY 59.5M | 0.05 | - |
| 2020 | CNY 59.5M | 0.05 | 28.4% |
| 2019 | CNY 2.37M | 0.00 | 0.8% |
| 2018 | CNY 120M | 0.10 | - |
| 2017 | CNY 80.6M | 0.07 | 28.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 30:10 on May 10, 2017.
Who owns Fuan Pharmaceutical Group Co
- Insiders 31.87%
- Institutions 0.39%
- Public & others 67.75%
- Shares outstanding 1.19B
- Free float 936M
Fuan Pharmaceutical Group Co company profile
- Company name
- Fuan Pharmaceutical Group Co
- Ticker
- 300194.SHE
- ISIN
- CNE1000011G4
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Mar 22, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,988
- Fiscal year end
- December
- Address
- No. 2, Huangyang Road, Chongqing, China, 401121
- Phone
- 86 23 6121 3011
- Website
- fapharm.com
About Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China and internationally. It offers APIs; intermediates; and FDFs, such as anti-tumor, specialty drugs, antibiotics, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd. in August 2013. The company was founded in 2004 and is headquartered in Chongqing, the People's Republic of China.
Fuan Pharmaceutical Group Co management
7- Mr. Lu WangGM & Executive Director · born 1984
- Mr. Tao HuangVice Chairman, Deputy GM & Director · born 1971
- Mr. Xue Song YuDeputy GM, CFO & Director · born 1969
- Mr. Qin TangSecretary of the Board of Directors & Director · born 1969
- Ms. Jing FengDeputy General Manager · born 1974
- Mr. Wei WangDeputy General Manager · born 1967
- Xiao Li GanAccounting Supervisor